Hussen Bashdar Mahmud, Sulaiman Seerwan Hamad Ameen, Abdullah Snur Rasool, Hidayat Hazha Jamal, Khudhur Zhikal Omar, Eslami Solat, Samsami Majid, Taheri Mohammad
Department of Biomedical Sciences, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq; Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq.
Department of Medical Laboratory Science, College of Health Sciences, Lebanese French University, Kurdistan Region, Erbil, Iraq.
Int J Biol Macromol. 2025 Apr;299:140134. doi: 10.1016/j.ijbiomac.2025.140134. Epub 2025 Jan 20.
Colorectal cancer (CRC) is a leading cause of death worldwide due to its aggressive nature and drug resistance, which limit traditional treatment effectiveness. Recent studies highlight the role of microRNAs (miRNAs) in tumorigenesis, metastasis, and chemotherapy resistance, with miRNA-155 emerging as a key player in CRC. miRNA-155 exerts dual effects, inducing drug resistance while serving as a potential therapeutic target. It regulates a wide array of mRNA transcripts associated with apoptosis, cell cycle regulation, and DNA repair, impacting various cellular pathways. Overexpression of miRNA-155 is linked to resistance against multiple chemotherapeutic drugs, promoting tumor cell survival, proliferation, and the epithelial-mesenchymal transition (EMT) process by repressing tumor suppressors and activating oncogenes. Additionally, miRNA-155 holds promise as a diagnostic and prognostic marker due to its association with CRC patient survival rates. However, its regulatory mechanisms across CRC subtypes remain unclear. This study provides insights into miRNA-155's role in CRC, focusing on its involvement in therapeutic resistance and potential as a therapeutic target. We also explore its significance as a prognostic biomarker and emphasize its therapeutic applications based on evidence from human, in vivo, in vitro, and clinical studies.
结直肠癌（CRC）因其侵袭性和耐药性，成为全球主要的死亡原因之一，这限制了传统治疗的效果。最近的研究强调了微小RNA（miRNA）在肿瘤发生、转移和化疗耐药中的作用，其中miRNA - 155在结直肠癌中成为关键因素。miRNA - 155发挥双重作用，既诱导耐药性，又作为潜在的治疗靶点。它调控与细胞凋亡、细胞周期调控和DNA修复相关的大量mRNA转录本，影响各种细胞途径。miRNA - 155的过表达与对多种化疗药物的耐药性有关，通过抑制肿瘤抑制因子和激活癌基因，促进肿瘤细胞存活、增殖以及上皮 - 间质转化（EMT）过程。此外，miRNA - 155因其与结直肠癌患者生存率的关联，有望成为诊断和预后标志物。然而，其在不同结直肠癌亚型中的调控机制仍不清楚。本研究深入探讨了miRNA - 155在结直肠癌中的作用，重点关注其在治疗耐药中的参与情况以及作为治疗靶点的潜力。我们还基于来自人体、体内、体外和临床研究的证据，探讨了其作为预后生物标志物的意义，并强调了其治疗应用。
